TET CpG sequence context specific DNA demeth-ylation shapes progression of IDH-mutant gliomas
Youri HoogstrateiD, Santoesha A. GhisaiiD, Levi van HijfteiD, Rania Head, Iris J. de HeeriD, Marta PadovaniD, Maurice de WitiD, Wies VallentgoediD, Angelo DipasqualeiD, Maarten M.J. WijnengaiD, Bas WeeninkiD, Rosa LuningiD, Sybren L. N. MaasiD, Adé la BrzobohatáiD, Michael WelleriD, Tobias WeißiD, Maximilian J. MairiD, Anna Sophie BerghoffiD, Adelheid Wöhrer, Albert JeltschiD, Johan A F KoekkoekiD, Hans Marten HazelbagiD, Mathilde C.M. KouwenhoveniD, Yongsoo KimiD, Bart A. WestermaniD, , Pim J. FrenchiD
Abstract
BackgroundTreatment decisions in IDH-mutant oligodendrogliomas are shaped by tumor aggressiveness, underscoring the need for objective grading of these malignant brain tumors. Material and MethodsWe collected 302 primary and recurrent resections from oligodendrogliomas and performed Ki-67 staining, proteomics and DNA methylation profiling. Results & conclusionDuring tumor progression, DNA methylation of oligodendrogliomas changed along a continuum. This continuum is linked to increased epigenetic aging, methylation of transcription factors and Ki-67+ cell density, and to large scale DNA demethylation. Demethylation was correlated with CpGs flanking sequences preferred by TET enzymes. We confirmed these findings in previously profiled astrocytomas, indicating IDH-mutant gliomas progress along a shared epigenetic axis. We developed an objective DNA methylation based prognostic continuous grading coefficient (CGC{psi}) that captured these changes and outperformed WHO grading for oligodendrogliomas. Our findings underscore the potential of DNA methylation-based grading to more accurately reflect tumor biology and inform clinical decision-making in IDH-mutant gliomas.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 8.84
- Field percentile
- top 3%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma
Santoesha A. Ghisai, Levi van Hijfte, … Youri Hoogstrate·Acta NeuropathologicaPeer-reviewed·Oct 9, 2024
- Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling
W. R. Vallentgoed, Youri Hoogstrate, … Pim J. French·Nature CancerPeer-reviewed·Aug 19, 2025
- Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications
T. M. Malta, C. F. Souza, … H. Noushmehr·bioRxiv·Sep 14, 2017
- Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced de-novo mutation in survival outliers of glioblastoma
T. Hwang, D. Mathios, … C.-K. Park·bioRxiv·Apr 16, 2018
- The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen
Tathiane Maistro Malta, Thaís S. Sabedot, … Peter S. LaViolette·Cancer ResearchPeer-reviewed·Dec 20, 2023
- One-Carbon Metabolic Reprogramming Stratifies Prognosis and Defines Distinct Biological States in IDH1-Mutant Gliomas
Mayank Bajaj, Roy Karnati·bioRxiv·Sep 9, 2026